Naratriptan Viatris (Naratriptan Hydrochloride)

Naratriptan is a triptan indicated for the acute treatment of migraine.

• Migraine: aborts acute migraine attacks and reduces associated symptoms such as nausea and sensitivity to light.
• Migraine with aura: provides rapid relief of headache and visual disturbances when taken at onset.
• Migraine in adults: offers a convenient oral option for patients seeking prompt symptom control.

• Naratriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve endings. Activation of 5‑HT1B receptors induces cranial vasoconstriction, while stimulation of 5‑HT1D receptors inhibits the release of pro‑inflammatory neuropeptides such as CGRP. Together these actions counteract the vascular and neurogenic components of migraine, leading to relief of headache pain.

Common and serious adverse reactions have been reported with Naratriptan use.

Common Side Effects

• Nausea: mild to moderate feeling of stomach upset.
• Dizziness: transient sensation of light‑headedness.
• Fatigue: general tiredness or lack of energy.
• Dry mouth: reduced salivation causing throat discomfort.

Serious or Rare Side Effects

• Chest pain: may indicate cardiac vasospasm.
• Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities when combined with serotonergic agents.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Hypertension: sudden increase in blood pressure.

When prescribing Naratriptan, clinicians should consider several precautionary measures to ensure patient safety.

• Cardiovascular disease: avoid use in patients with uncontrolled hypertension, coronary artery disease, or history of myocardial infarction.
• Serotonergic agents: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, MAO inhibitors, or other triptans.
• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Age restrictions: safety and efficacy have not been established in children or adolescents.
• Storage: Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with other medicines; understanding the level of interaction helps guide safe co‑administration.

Major Interactions (Avoid)

• Ergot alkaloids: concurrent use can cause severe vasospasm and ischemia.
• SSRIs, SNRIs, MAO inhibitors: combined use increases the risk of serotonin syndrome.
• Other triptans: additive vasoconstrictive effects may lead to cardiovascular events.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance hypotensive effects of Naratriptan.
• Antihypertensive agents: monitor blood pressure for additive lowering.
• CYP3A4 inhibitors: may raise Naratriptan plasma concentrations, requiring dose adjustment.